616 related articles for article (PubMed ID: 21484190)
1. Proteasome inhibitors in cancer therapy.
Crawford LJ; Walker B; Irvine AE
J Cell Commun Signal; 2011 Jun; 5(2):101-10. PubMed ID: 21484190
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Crawford LJ; Walker B; Irvine AE
Front Biosci; 2008 May; 13():4285-96. PubMed ID: 18508511
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
[TBL] [Abstract][Full Text] [Related]
4. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors in cancer therapy.
Testa U
Curr Drug Targets; 2009 Oct; 10(10):968-81. PubMed ID: 19548862
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Johnson DE
Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
[TBL] [Abstract][Full Text] [Related]
10. [Proteasome inhibitor].
Yagi H
Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Mattern MR; Wu J; Nicholson B
Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin proteasome pathway from bench to bedside.
Orlowski RZ
Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
[TBL] [Abstract][Full Text] [Related]
13. From bortezomib to other inhibitors of the proteasome and beyond.
Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
16. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Mujtaba T; Dou QP
Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
[TBL] [Abstract][Full Text] [Related]
17. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
18. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
19. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Shahshahan MA; Beckley MN; Jazirehi AR
Am J Cancer Res; 2011; 1(7):913-24. PubMed ID: 22016836
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma.
Jayaweera SPE; Wanigasinghe Kanakanamge SP; Rajalingam D; Silva GN
Front Oncol; 2021; 11():740796. PubMed ID: 34858819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]